Lantheus Holdings, Inc. (LNTH) Stock: Price, Forecast & Analyst Target
Lantheus Holdings, Inc. (LNTH) — MoonshotScore 96/100 (Exceptional band), calculated Nov 18, 2026. Price $102.10 (0.00%), as of the Nov 20, 2026 trading session; market cap $6.68B. Expected results Feb 25, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Lantheus Holdings, Inc. · LNTH · NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
Research dated 2026-09-13: Lantheus supplies the specialized imaging agents that hospitals use to illuminate cancer cells and cardiac tissues during scans. The company transformed its financial profile by capturing the prostate cancer diagnostic market, leaving its valuation heavily dependent on extending that dominance while younger therapeutic candidates advance.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · Lantheus Holdings (LNTH)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality, a fortress balance sheet and elite growth, with no real weak spot — fairly priced, so not a bargain entry; the market is already moving on it. Business Quality: Elite; Financial Safety: Fortress; Valuation: Fair; Growth Durability: Compounding; Momentum: Surging.
- quarterly revenue $384M (Q3 FY2025, quarter ended Sep 2025)
- EPS beat 0 of the last 4 reports
- Altman Z 5.64 · Piotroski F 8
Helping: business quality, balance-sheet strength, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 94 | Exceptional | |
| 94 | Exceptional | |
| 94 | Exceptional | |
| 96 | Exceptional | |
| 96 | Exceptional | |
| 96 | Exceptional |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $102.10 | |
| Change on the day | 0.00% | |
| 52-week range | $51.84–$111.86 | |
| Market capitalisation | $6.68B | — |
| Price / earnings (trailing) | 24.59 | |
| Shares traded on the day | 1.07M | |
| Beta (volatility vs the S&P 500) | 0.03 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
How to read these dates
Estimated dates can change.
Other perspectives
Council score for Lantheus Holdings (LNTH): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 21, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 20, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
The Munger lens reads the current price as fairly valued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is Lantheus Holdings (LNTH), and what does it report?
Short answer · as of
Grouped with traditional generic drugmakers, Lantheus operates a fundamentally different model built on nuclear medicine and ultrasound contrast materials.
Research dated 2026-09-13.
The company generates revenue by selling individual radioactive doses and microbubble injections that clinics administer right before running patient scans.
The bulk of the top line relies directly on an injectable agent that highlights prostate cancer cells on imaging equipment, supplemented by an established cardiac ultrasound product. Measuring this business means tracking specialized diagnostic procedure volumes rather than daily pharmacy prescriptions.
What do the latest results show for Lantheus Holdings (LNTH)?
Short answer · as of
The most recent reported quarter, Q3 FY2025, carried revenue of $384M.
Research dated 2026-09-13.
Recent financial disclosures illustrate a stabilizing top line following an extended period of intense expansion, with recent sales missing analyst projections. Even as revenue growth cools, gross profitability remains exceptionally strong, reflecting the premium pricing power of specialized radiopharmaceuticals.
However, sustained research commitments continue to absorb a significant portion of operating income. The underlying mechanism is a maturing adoption curve for the flagship prostate cancer imaging agent, shifting the financial narrative from explosive market penetration toward steady cash generation.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $389.91M Nov 5, 2026
- Latest report · revenue estimate
- $355.74M Nov 5, 2026
- Latest report · revenue vs estimate
- Above estimate Nov 5, 2026
- Latest report · EPS vs estimate
- Above estimate Nov 5, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Nov 5, 2026 | $389.91M | $355.74M | $1.6800 | $1.2300 |
| Aug 6, 2026 | $388.18M | $363.23M | $1.5500 | $1.3000 |
| May 7, 2026 | $377.33M | $354.48M | $1.4600 | $1.2500 |
| Feb 26, 2026 | $406.79M | $366.99M | $1.6700 | $1.1800 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2025 | $384M | $28M | $0.41 (diluted) |
| Q4 FY2025 | $407M | $54M | $0.82 (diluted) |
| Q1 FY2026 | $377M | $118M | $1.80 (diluted) |
| Q2 FY2026 | $388M | $75M | $1.11 (diluted) |
What are the financial strengths and risks for Lantheus Holdings (LNTH)?
Short answer
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-13.
Operating cash flow consistently outpaces capital requirements, providing the business with substantial liquidity to fund its clinical pipeline and strategic collaborations. The balance sheet supports this with manageable leverage and ample short-term investments that thoroughly cover immediate liabilities.
The acute risk lies in revenue concentration rather than solvency. Because the income statement depends heavily on a specific diagnostic agent, regulatory approval of competing prostate imaging tools or adjustments to clinical reimbursement rates would directly threaten the core profit engine.
What should you watch next at Lantheus Holdings (LNTH)?
Short answer · as of
The next earnings report is expected on Feb 25, 2027.
Research dated 2026-09-13.
The upcoming reporting cycle serves as a critical test of whether the company can reaccelerate its sales volume or if recent plateaus represent a structural ceiling for its current portfolio. Analysts have issued notable downgrades, signaling a market recalibration toward a more mature, slower-growth expectation.
Investors should monitor clinical updates regarding the radiopharmaceutical therapeutic pipeline, as advancing these specialized treatments remains the clearest path to diversifying revenue away from pure diagnostics.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The newest quarter held here (Q3 FY2025) was filed Nov 6, 2025 — 12 months ago.
Checked against the records this page reads, on the dates shown above.
How does Lantheus Holdings compare with its peers?
Short answer
Lantheus Holdings's score ranks 2nd of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Unlike broad pharmaceutical peers that rely on recurring daily prescriptions for chronic care, Lantheus operates entirely within the episodic environment of the clinical imaging suite. Its core products involve radioactive isotopes that require complex manufacturing and highly synchronized distribution networks to accommodate rapid decay times.
This severe logistical complexity creates formidable barriers to entry, insulating margins more effectively than traditional patent cliffs. However, this same specialization strictly caps total addressable demand to the absolute volume of specific hospital scanning procedures performed.
| Company | Price | Market value | Score |
|---|---|---|---|
| $108.10 Nov 19, 2026 | $8.79B | 97 5-pillar Nov 18, 2026 | |
| Lantheus Holdings (LNTH) — this page | $102.10 | $6.68B | 96 |
| $68.55 Nov 20, 2026 | $1.56B | 94 5-pillar Nov 18, 2026 | |
| $36.48 Nov 20, 2026 | $1.46B | 92 5-pillar Nov 18, 2026 | |
| $14.89 Nov 20, 2026 | $12.4B | 77 5-pillar Nov 18, 2026 | |
| $28.61 Nov 20, 2026 | $5.94B | 74 5-pillar Nov 18, 2026 | |
| $13.22 Nov 20, 2026 | $2.30B | 70 5-pillar Nov 18, 2026 | |
| $21.12 Nov 20, 2026 | $7.36B | 66 5-pillar Nov 18, 2026 | |
| $300.43 Nov 20, 2026 | $8.40B | 60 5-pillar Nov 18, 2026 | |
| $4.36 Nov 19, 2026 | $2.16B | 47 5-pillar Nov 18, 2026 | |
| $26.29 Nov 19, 2026 | $13.1B | 35 5-pillar Nov 18, 2026 | |
| $19.63 Nov 20, 2026 | $22.5B | 35 5-pillar Nov 18, 2026 | |
| $8.22 Nov 20, 2026 | $3.08B | 30 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $102.50 – $109.00
- Consensus target
- $104.38
- Median target
- $102.50
Consensus record · Captured .
Measured against a quoted price of $102.10 (as of Nov 20, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Aug 31, 2026
- Transactions
- 3
- Identified insiders
- 3
- Purchases
- 0
- Sales
- 0
- Other transactions
- 3
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held LNTH in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported LNTH in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Lantheus Holdings (LNTH)?
- Lantheus Announces Positive Results from Phase 3 Studies of TAUKLARIFY™ for Alzheimer's Disease
- Lantheus Presents Data from Two Pivotal Phase 3 Studies of TAUKLARIFY (Florquinitau F 18 Injection) PET Imaging in Early Alzheimer’s Disease
- Lantheus to Sell CDMO Business, New Jersey Manufacturing Facility to PharmaLogic
- PharmaLogic to Acquire Lantheus' CDMO Business and Springfield Manufacturing Facility
LNTH Healthcare Stock FAQ
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
How does PYLARIFY contribute to the overall business?
The prostate cancer imaging agent acts as the primary financial engine, generating the absolute majority of total revenue. Its successful adoption transformed the company from a modest contrast provider into a highly profitable radiopharmaceutical leader.
What role does DEFINITY play in the product portfolio?
As a microbubble contrast agent for cardiac ultrasounds, this legacy product provides a steady, established income stream that complements the newer oncology diagnostics. It serves as a reliable secondary pillar that helps fund ongoing therapeutic research.
How do the logistical requirements of radioactive isotopes affect operations?
Materials like technetium and iodine possess incredibly brief shelf lives, requiring immediate dispatch from manufacturing sites directly to medical centers. This rapid decay mandates a flawless distribution network, which adds significant operational expense but simultaneously limits external competition.
Why are analysts adjusting their ratings on the stock?
Recent downgrades reflect concerns that the period of rapid expansion for the flagship diagnostic tool has concluded. Firms are realigning their models to account for a stabilizing sales environment and increasing competition in the specialized imaging space.
What is the LNTH stock price today?
The last price recorded for Lantheus Holdings, Inc. (LNTH), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the LNTH price target?
The analyst consensus price target for Lantheus Holdings, Inc. (LNTH), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 43 figures on this page — 38 from Financial Modeling Prep (FMP), 2 with no recorded source, 2 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-13), by section of the research
ETFs that hold LNTH
Funds in our ETF coverage that list LNTH among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| IVSS ETF | 1.24% |